Karyopharm Therapeutics (KPTI) PT Raised to $24 at RBC Capital; 'We Would Be Buyers'
Tweet Send to a Friend
RBC Capital raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $24.00 (from $22.00) while maintaining a Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
